Betta Pharma Secures Exclusive Greater‑China Rights to Gensciences’ Long‑Acting Factor VIII Therapy
Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework...
Betta Pharmaceuticals
Betta Pharmaceuticals Secures NMPA Approval for MCLA‑129/Ensartinib Combination in Advanced Solid Tumors
China-based Betta Pharmaceuticals (SHE: 300558) announced that China’s National Medical Products Administration (NMPA) has approved...
Betta Pharmaceuticals’ Kangmeina Approved by NMPA for Advanced Breast Cancer Treatment
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received market approval from...
EyePoint’s Partner Betta Completes Enrollment for Duravyu’s Pivotal Phase III Study
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), the US partner of China-based Betta Pharmaceuticals (SHE: 300558), announced...
Betta Pharmaceuticals Partners with BioRay for Herceptin Biosimilar Anruize
China-based Betta Pharmaceuticals (SHE: 300558) announced a strategic partnership with fellow domestic firm BioRay Biopharmaceutical....
Betta Pharmaceuticals Secures Macau Approval for Ensartinib
China-based Betta Pharmaceuticals (SHE: 300558) announced a market approval filing in Macau for its ensartinib,...
Betta Pharma Files for EMA Approval of ALK Inhibitor Ensartinib
Betta Pharmaceuticals (SHE: 300558) announced the initiation of a market approval filing with the European...
Betta Pharmaceuticals Gains NMPA Approval for BPI-452080 Clinical Study
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) announced that it has received approval from the...
FDA Approves Xcovery Holdings’ Ensartinib for Untreated ALK-Positive NSCLC Patients
On December 18, 2024, the Food and Drug Administration (FDA) granted approval for Betta Pharmaceutical...
Healthgen Biotechnology’s Plant-Made Albumin Breakthrough: A Milestone in Serum Therapy
On November 30th, Healthgen Biotechnology Corp. announced a significant research outcome at the 9th Pharmaceutical...
E-nitiate Biopharmaceuticals Strikes Licensing Deal with Joincare for QY101 Inhaler Rights
China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a joint venture between VivaVision Biotech and Betta Pharmaceuticals...
Betta Pharmaceuticals’ MCLA-129 Approved for Clinical Trial in Advanced Solid Tumors
China’s Betta Pharmaceuticals (SHE: 300558) has announced that it has received clinical trial approval from...
Beijing Mabworks Biotech’s IPO Application Accepted by Beijing Stock Exchange
Beijing Mabworks Biotech Co., Ltd, a China-based biotech firm, has seen its initial public offering...
Reprogenix Secures Over RMB100 Million in Series A Financing Led by China Venture Capital
Hangzhou-based stem cell specialist Reprogenix has announced the successful completion of a Series A financing...
Betta Pharmaceuticals’ MCLA129 for Advanced Solid Tumors Accepted for Review by China’s NMPA
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a pharmaceutical company based in China, has announced that...
Betta Pharmaceuticals Reports Strong H1 2024 Revenue Growth and Advances in Drug Development
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has reported its financial results...
Betta Pharmaceuticals’ EYP-1901 Implant Secures NMPA Clinical Trial Nod for Wet AMD
Betta Pharmaceuticals (SHE: 300558) has announced that it has received clinical trial approval from China’s...
Betta Pharmaceuticals Files for Market Approval of CDK4/6 Inhibitor BPI-16350 in China
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has...
EyePoint Pharmaceuticals’ Durvayu Fails to Meet Primary Endpoint in NPDR Trial
EyePoint Pharmaceuticals Inc., (NASDAQ: EYPT) has announced that its drug candidate Durvayu (vorolanib intravitreal insert;...
Betta Pharmaceuticals’ BPI-16350 Combo Therapy Shows Improved PFS in Breast Cancer Trial
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced an update on its Phase III...